The Effect of Dates on Plasma Lipids, Oxidative Stress and the Atherogenicity of Serum in Healthy Adults

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2008 by HaEmek Medical Center, Israel.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
HaEmek Medical Center, Israel
ClinicalTrials.gov Identifier:
NCT00750789
First received: August 17, 2008
Last updated: September 10, 2008
Last verified: September 2008
  Purpose

It has been proven in in-vitro studies that dates decrease the oxidative stress in serum. There have been no in-vivo studies to this date. The current study aims to test whether dates consumption by healthy adults decreases serum oxidative stress and improves serum PON1 activity and serum lipid profile.


Condition Intervention Phase
Atherosclerosis
Dietary Supplement: dates
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention

Resource links provided by NLM:


Further study details as provided by HaEmek Medical Center, Israel:

Primary Outcome Measures:
  • serum oxidative stress [ Time Frame: 30 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • serum lipid profile [ Time Frame: 30 days ] [ Designated as safety issue: No ]

Estimated Enrollment: 10
Study Start Date: September 2008
Estimated Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Dietary Supplement: dates
    5 maedjool dates or 7 emery dates per day for 2 weeks each with a washout period of 2 weeks between
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy volunteers

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00750789

Contacts
Contact: Wasseem Rock, MD 04-6495135 wasseem_rock@yahoo.com

Locations
Israel
Emek Medical Center Not yet recruiting
Afula, Israel
Contact: Wasseem Rock, MD    04-6495135      
Sponsors and Collaborators
HaEmek Medical Center, Israel
Investigators
Principal Investigator: Wasseem Rock Emek Medical Center
  More Information

No publications provided

Responsible Party: Wasseem Rock, emek medical center
ClinicalTrials.gov Identifier: NCT00750789     History of Changes
Other Study ID Numbers: 0061-08-EMC
Study First Received: August 17, 2008
Last Updated: September 10, 2008
Health Authority: Israel: Ministry of Health

Additional relevant MeSH terms:
Atherosclerosis
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on September 29, 2014